Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16639096 | 0.85 | PIK3CD (0.41) | PIK3CAPIK3CDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL17053407 | 0.84 | PIK3CA (0.40) | PIK3CAPIK3CDALOX5APFEN1PRKCI | |
| SCHEMBL16639077 | 0.83 | PRKCI (0.32) | PIK3CAPIK3CDPRKCI | |
| SCHEMBL16639073 | 0.82 | PIK3CA (0.38) | PIK3CAPIK3CDSMN1; SMN2EPHB4LMNA | |
| SCHEMBL17946922 | 0.79 | AURKA (0.45) | PIK3CAPIK3CD | |
| SCHEMBL16639074 | 0.79 | PIK3CA (0.37) | PIK3CAPIK3CDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16639097 | 0.76 | CYP2A6 (0.43) | PIK3CAPIK3CD | |
| SCHEMBL17053399 | 0.75 | PIK3CA (0.52) | PIK3CAPIK3CD | |
| SCHEMBL17946631 | 0.75 | PIK3CD (0.45) | PIK3CAPIK3CDKDM4ELMNA | |
| SCHEMBL16639118 | 0.75 | TXN (0.36) | KDM4EALDH1A1SMN1; SMN2EPHB4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2860181-B1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| EP-2860181-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | Shanghai Yingli Science and Technology Co., Ltd (CN) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CD 2/4885KDM4E 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.